Immunogenicity, Safety, and Cross‐Reactivity of an Inactivated, Adjuvanted, Prototype Pandemic Influenza (H5N1) Vaccine: A Phase II, Double‐Blind, Randomized Trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.